- Home
- NXTC vs IPA Comparison
NXTC vs IPA Comparison
Compare NXTC & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- IPA
- Stock Information
- Founded
- NXTC 2015
- IPA 1983
- Country
- NXTC United States
- IPA Canada
- Employees
- NXTC N/A
- IPA N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- IPA Health Care
- Exchange
- NXTC Nasdaq
- IPA Nasdaq
- Market Cap
- NXTC 20.6M
- IPA 19.3M
- IPO Year
- NXTC 2019
- IPA 2017
- Fundamental
- Price
- NXTC $0.40
- IPA $0.38
- Analyst Decision
- NXTC Strong Buy
- IPA Strong Buy
- Analyst Count
- NXTC 2
- IPA 2
- Target Price
- NXTC $3.50
- IPA $4.00
- AVG Volume (30 Days)
- NXTC 99.1K
- IPA 2.3M
- Earning Date
- NXTC 03-06-2025
- IPA 03-28-2025
- Dividend Yield
- NXTC N/A
- IPA N/A
- EPS Growth
- NXTC N/A
- IPA N/A
- EPS
- NXTC N/A
- IPA N/A
- Revenue
- NXTC N/A
- IPA $16,581,105.00
- Revenue This Year
- NXTC N/A
- IPA $1.88
- Revenue Next Year
- NXTC N/A
- IPA $9.90
- P/E Ratio
- NXTC N/A
- IPA N/A
- Revenue Growth
- NXTC N/A
- IPA 1.35
- 52 Week Low
- NXTC $0.35
- IPA $0.27
- 52 Week High
- NXTC $2.49
- IPA $1.50
- Technical
- Relative Strength Index (RSI)
- NXTC 22.20
- IPA 44.80
- Support Level
- NXTC $0.49
- IPA $0.32
- Resistance Level
- NXTC $0.67
- IPA $0.46
- Average True Range (ATR)
- NXTC 0.09
- IPA 0.05
- MACD
- NXTC -0.02
- IPA -0.00
- Stochastic Oscillator
- NXTC 12.74
- IPA 42.70
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.